Eurofins Genomics launches EXTREmers

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/ktsimage)
(Image: iStock/ktsimage)

Related tags Genetics

Eurofins Genomics has launched its EXTREmer oligonucleotides in the US – adding another ‘tool’ to help researchers advance drug discovery.

EXTREmer oligonucleotides are extremely long oligos developed using high-fidelity synthesis chemistry on the company's new DNA synthesis platform.

According to the company, the new service will be helpful for generating oligos for DNA-directed RNA interference, capture probes, or control standards in qPCR experiments, among other applications.

Oligos are used routinely in genetic studies to make effective and specific modifications in various genes​,” Sanjay Singh, technical marketing and product manager, Eurofins Genomics, told us.

Biotech and pharmaceutical firms use these custom made DNA oligos of different lengths to make advances towards the discovery of better drugs or high-performing crops​,” he added.

Singh explained EXTREmers, as well as the company’s regular oligos, help scientists “advance their specific goals efficiently​.”

Jeff Nelson, head of process development for high-throughput synthesis at the company, also told us the new offering saves time, effort, and resources for researchers.

Additional benefits include the ability to generate oligos in low quantities and significantly reduce the effort required to construct genes​,” he added. “In summary, researchers can synthesize more complex ‘designer’ genes with less effort and a higher chance of success using EXTREmers​.”

Related topics Bio Developments Bio-Outsourcing

Related news

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more